analyzeportfolio
NYSE · Industrials

NU SKIN ENTERPRISES, INC. (NUS)

As-reported financials and SEC filings for NU SKIN ENTERPRISES, INC. The latest annual period is FY2025. The latest reported quarter is Q2 FY2026. Financial statements come straight from the company’s EDGAR filings; valuation figures such as P/E and market cap use market data.

About NU SKIN ENTERPRISES, INC.

Nu Skin Enterprises, Inc. develops and sells beauty and wellness products in nearly 50 markets worldwide through direct selling, primarily using person-to-person marketing and digital platforms. Its main product categories include premium-quality beauty products such as skincare devices and cosmetics, and wellness products like nutritional supplements, marketed under brands including Nu Skin, Pharmanex, and ageLOC. The company also invests in consumer, technology, and manufacturing businesses through its Rhyz Inc. division to support its core operations.

Snapshot

Revenue
$1.49B
Revenue growth (YoY)
-14.3%
Net income
$160.2M
Diluted EPS
$3.18
Gross margin
69.4%
Operating margin
4.4%
Net margin
10.8%
FCF margin
3.1%
ROE
19.9%
net income / fiscal-year-end equity
P/E
1.5×
trailing when available, otherwise FY EPS
Market cap
$236.1M
Long-term debt / equity
0.25×
non-current term debt only

Fundamentals are from SEC filings for FY2025, the latest annual period (ended December 31, 2025). P/E and market cap are derived from stored market prices, last retrieved on a rolling basis and typically within the past week.

What changed at Nu Skin Enterprises

  • Revenue fell 14.3% to $1.5B in FY2025, after a 12.0% decline the year before.
  • Operating margin is 4.4% in FY2025, -4.3 pp against 8.7% in FY2021.
  • Most recent quarter Q2 FY2026: revenue $320M, down 17.1% from Q2 FY2025.
  • Free cash flow was $46M in FY2025, 3.1% of revenue.
  • Net income turned positive at $160M in FY2025, from a $147M loss in FY2024.

Computed from the as-reported figures in the statements below. A change we cannot state from filed figures is left out rather than estimated.

Peer comparison

Where Nu Skin Enterprises’s fundamentals sit among the 684 Industrials companies. Each figure is ranked only against peers that report it, from lowest (left) to highest (right).

Gross margin69.4%
95th percentile of 466
Operating margin4.4%
47th percentile of 605
Net margin10.8%
78th percentile of 645
FCF margin3.1%
42nd percentile of 562
Revenue growth (YoY)-14.3%
10th percentile of 668
ROE19.9%
82nd percentile of 600
P/E1.5×
1st percentile of 435
Long-term debt / equity0.25×
32nd percentile of 409
Short interest5.96d
83rd percentile of 676

Nu Skin Enterprises’s P/E of 1.5 ranks in the 1st percentile of the 435 peers with a meaningful P/E. Nu Skin Enterprises’s gross margin of 69.4% ranks in the 95th percentile of the 466 Industrials companies reporting it. Nu Skin Enterprises’s revenue growth of -14.3% ranks in the 10th percentile of the 668 Industrials companies reporting it.

No reported insider transactions (codes P/S) in the last 90 days. For context, about 15% of companies in the universe saw any reported insider purchase (code P) in the same window. Browse insider activity →

Percentiles describe where a figure sits among sector peers reporting it (100th = highest). They are position within a peer group, not a rating, and not investment advice. Short interest ranking uses days to cover from FINRA Consolidated Short Interest data; FINRA is the owner and source of that data, included at no additional charge.

Institutional ownership

Held by 5 quant / multi-strat books among the superinvestors we track; no conviction manager currently reports a position.

Conviction investors
0
+5 quant / multi-strat
Initiated / added
2
0 new, 2 added
Reduced / exited
5
3 trimmed, 2 exited
Combined position
$24.1M
reported long value
InvestorAs ofPosition valueSharesChange
Renaissance TechnologiesquantQ2 2026$8.5M1.6MReduced
Two Sigma InvestmentsquantQ2 2026$6.2M1.2MAdded
AQR Capital ManagementquantQ2 2026$4.0M789.1KReduced
Citadel AdvisorsquantQ2 2026$3.5M654.6KAdded
D. E. ShawquantQ2 2026$2.0M380.7KReduced

No longer held by: Millennium Management (as of Q2 2026), Point72 Asset Management (as of Q2 2026)

From quarterly Form 13F filings, which can be up to 45 days delayed. Long US-listed positions only: excludes short positions, options, cash, bonds, and non-US holdings, so this is not a manager’s complete portfolio. Counts are of the investors we track, not all institutions. Not investment advice.

Recent insider activity

Non-derivative buys and sells (codes P/S) reported by officers, directors and 10% owners on SEC Form 4.

Buys (90d)
0
code P
Bought (90d)
code P value
Sells (90d)
0
Reported activity
Quiet
by $ value, 90d
Trade dateInsiderTypeSharesPriceValue
2026-06-02
filed 2026-06-03
Winett James MDirectorSell7.2K$5.62$40K
2026-06-01
filed 2026-06-03
WOODBURY EDWINA DDirectorSell7.2K$5.70$41K
2026-05-11
filed 2026-05-12
Nathanson LauraDirectorSell2.7K$6.73$18K

Reported non-derivative purchases and sales (codes P/S) — which may be open-market or private; excludes option exercises, grants, and shares withheld for taxes. Dates shown are the trade date; a Form 4 can be filed days to years later. A sale can be routine (e.g. a pre-set 10b5-1 plan), so read individual transactions in context. From SEC Form 4. Not investment advice.

Short interest

Total shares sold short as of each twice-monthly FINRA settlement. Rising short interest means more investors are positioned against the stock; days to cover estimates how many trading days of average volume that position represents.

Shares short
4.4M
settled 2026-08-14
Change vs prior
-4.0%
vs previous settlement
Days to cover
5.96
at avg daily volume
Avg daily volume
745.0K
FINRA reported
SettlementShares shortChangeDays to cover
2026-08-144.4M-4.0%5.96
2026-07-314.6M+10.5%10.00
2026-07-154.2M+10.2%5.99
2026-06-303.8M+5.2%3.53
2026-06-153.6M+16.8%5.27
2026-05-293.1M+0.2%4.49
2026-05-153.1M+15.7%4.52
2026-04-302.7M+7.0%6.64

Source: FINRA Consolidated Short Interest. FINRA is the owner and source of the FINRA-supplied data, which is included at no additional charge for your own personal or professional use; republishing or redistributing it is not permitted. Settlement dates are shown; FINRA publishes each settlement about nine business days later, so the latest figure can be two to four weeks old. Not presented as a percentage of float. No FINRA endorsement of this product is implied. Not investment advice.

Income statement (as reported)

 FY2025FY2024FY2023FY2022FY2021
Revenue$1.49B$1.73B$1.97B$2.23B$2.70B
Gross profit$1.03B$1.18B$1.36B$1.59B$2.02B
Operating income$65.8M$-151.6M$48.3M$110.8M$234.0M
Net income$160.2M$-146.6M$8.6M$104.8M$147.3M
Diluted EPS$3.18$-2.95$0.17$2.07$2.86

Figures as reported to the SEC. Underlined values link to the filing they came from; dotted values are calculated by us from reported figures; “adj” means restated for a stock split (hover to see the figure as filed). Full details: where the numbers come from.

Balance sheet (as reported)

Figures as reported to the SEC. Underlined values link to the filing they came from; dotted values are calculated by us from reported figures; “adj” means restated for a stock split (hover to see the figure as filed). Full details: where the numbers come from.

Cash flow (as reported)

 FY2025FY2024FY2023FY2022FY2021
Operating cash flow$80.3M$111.7M$118.6M$108.1M$141.6M
Capital expenditure$34.3M$41.6M$58.5M$59.1M$68.6M
Free cash flow$46.0M$70.2M$60.1M$49.0M$73.0M

Figures as reported to the SEC. Underlined values link to the filing they came from; dotted values are calculated by us from reported figures; “adj” means restated for a stock split (hover to see the figure as filed). Full details: where the numbers come from.

Quarterly trend (as reported)

QuarterRevenueRevenue YoYNet incomeDiluted EPS
Q2 FY2026$320.1M-17.1%$-249.8M$-5.14
Q1 FY2026$320.6M-12.0%$1.8M$0.04
Q4 FY2025$370.3M-16.9%$14.5M$0.29
Q3 FY2025$364.2M-15.3%$17.1M$0.34
Q2 FY2025$386.1M-12.1%$21.1M$0.43
Q1 FY2025$364.5M-12.7%$107.5M$2.14
Q4 FY2024$445.6M-8.8%$-36.1M$-0.73
Q3 FY2024$430.1M-13.8%$8.3M$0.17

Latest 8 reported quarters, from company XBRL filings on SEC EDGAR.

Company facts

ExchangeNYSE
SectorIndustrials
SIC industryWholesale-Drugs, Proprietaries & Druggists' Sundries
Latest annual periodFY2025 (ended December 31, 2025)
Latest reported quarterQ2 FY2026 (ended June 30, 2026)
Oldest indexed filing2013
SEC CIK1021561

Selected SEC filings

10-Q2026-08-10
View on EDGAR →
10-Q2026-05-08
View on EDGAR →
8-K2026-08-21
View on EDGAR →
8-K2026-08-10
View on EDGAR →
8-K2026-05-29
View on EDGAR →
8-K2026-05-08
View on EDGAR →

Largest Industrials peers

All Industrials companies →

Monitor NUS

Get an alert when Nu Skin Enterprises files something material, see which superinvestors own it, and ask its filings a question with cited answers.

Monitor NUS free

Includes one free filing-grounded research answer. Or check your whole portfolio, no account needed.

Data sourced from SEC EDGAR. Figures are as-reported and may be unaudited or restated; verify against the source filing before relying on them. Informational only. Not investment advice.